<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:01:33Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9194804" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9194804</identifier>
        <datestamp>2022-06-15</datestamp>
        <setSpec>rheumatology</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Rheumatology (Oxford)</journal-id>
              <journal-id journal-id-type="iso-abbrev">Rheumatology (Oxford)</journal-id>
              <journal-id journal-id-type="publisher-id">brheum</journal-id>
              <journal-title-group>
                <journal-title>Rheumatology (Oxford, England)</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1462-0324</issn>
              <issn pub-type="epub">1462-0332</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9194804</article-id>
              <article-id pub-id-type="pmcid">PMC9194804</article-id>
              <article-id pub-id-type="pmc-uid">9194804</article-id>
              <article-id pub-id-type="pmid">33956056</article-id>
              <article-id pub-id-type="pmid">33956056</article-id>
              <article-id pub-id-type="doi">10.1093/rheumatology/keab381</article-id>
              <article-id pub-id-type="publisher-id">keab381</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Science</subject>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00360</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in
patients with moderate-to-severe active systemic lupus erythematosus</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6712-1585</contrib-id>
                  <name>
                    <surname>Furie</surname>
                    <given-names>Richard A</given-names>
                  </name>
                  <xref rid="keab381-aff1" ref-type="aff">1</xref>
                  <xref rid="keab381-cor1" ref-type="corresp"/>
                  <!--RFurie@northwell.edu-->
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3047-500X</contrib-id>
                  <name>
                    <surname>Bruce</surname>
                    <given-names>Ian N</given-names>
                  </name>
                  <xref rid="keab381-aff2" ref-type="aff">2</xref>
                  <xref rid="keab381-aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dörner</surname>
                    <given-names>Thomas</given-names>
                  </name>
                  <xref rid="keab381-aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Leon</surname>
                    <given-names>Manuel Gustavo</given-names>
                  </name>
                  <xref rid="keab381-aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Leszczyński</surname>
                    <given-names>Piotr</given-names>
                  </name>
                  <xref rid="keab381-aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Urowitz</surname>
                    <given-names>Murray</given-names>
                  </name>
                  <xref rid="keab381-aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Haier</surname>
                    <given-names>Birgit</given-names>
                  </name>
                  <xref rid="keab381-aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jimenez</surname>
                    <given-names>Teri</given-names>
                  </name>
                  <xref rid="keab381-aff9" ref-type="aff">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Brittain</surname>
                    <given-names>Claire</given-names>
                  </name>
                  <xref rid="keab381-aff10" ref-type="aff">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Liu</surname>
                    <given-names>Jiajun</given-names>
                  </name>
                  <xref rid="keab381-aff11" ref-type="aff">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Barbey</surname>
                    <given-names>Catherine</given-names>
                  </name>
                  <xref rid="keab381-aff12" ref-type="aff">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stach</surname>
                    <given-names>Christian</given-names>
                  </name>
                  <xref rid="keab381-aff8" ref-type="aff">8</xref>
                </contrib>
              </contrib-group>
              <aff id="keab381-aff1"><label>1</label><institution>Northwell Health</institution>, Great Neck, NY, <country country="US">USA</country></aff>
              <aff id="keab381-aff2">
                <label>2</label>
                <institution>NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS
Trust</institution>
                <country country="GB"/>
              </aff>
              <aff id="keab381-aff3"><label>3</label><institution>Centre for Musculoskeletal Research, University of Manchester, Manchester
Academic Health Science Centre</institution>, Manchester, <country country="GB">UK</country></aff>
              <aff id="keab381-aff4"><label>4</label><institution>Charité Berlin</institution>, Berlin, <country country="DE">Germany</country></aff>
              <aff id="keab381-aff5"><label>5</label><institution>Investigaciones Clínicas</institution>, Lima, Peru</aff>
              <aff id="keab381-aff6"><label>6</label><institution>Poznań University of Medical Sciences</institution>, Poznań, <country country="PL">Poland</country></aff>
              <aff id="keab381-aff7"><label>7</label><institution>Toronto Western Hospital</institution>, Toronto, Ontario, <country country="CA">Canada</country></aff>
              <aff id="keab381-aff8"><label>8</label><institution>UCB Pharma, Monheim am Rhein</institution>, <country country="DE">Germany</country></aff>
              <aff id="keab381-aff9"><label>9</label><institution>UCB Pharma</institution>, Raleigh, NC, <country country="US">USA</country></aff>
              <aff id="keab381-aff10"><label>10</label><institution>UCB Pharma</institution>, Slough, <country country="GB">UK</country></aff>
              <aff id="keab381-aff11"><label>11</label><institution>Biogen</institution>, Cambridge, MA, <country country="US">USA</country></aff>
              <aff id="keab381-aff12"><label>12</label><institution>Biogen</institution>, Baar, <country country="CH">Switzerland</country></aff>
              <author-notes>
                <corresp id="keab381-cor1">Correspondence to: Richard A. Furie, Northwell Health, Great
Neck, NY, USA. E-mail: <email>RFurie@northwell.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2021-05-06">
                <day>06</day>
                <month>5</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>06</day>
                <month>5</month>
                <year>2021</year>
              </pub-date>
              <volume>60</volume>
              <issue>11</issue>
              <fpage>5397</fpage>
              <lpage>5407</lpage>
              <history>
                <date date-type="received">
                  <day>05</day>
                  <month>1</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-recd">
                  <day>14</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2021. Published by Oxford University Press on behalf of
the British Society for Rheumatology.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits
non-commercial re-use, distribution, and reproduction in any medium, provided the
original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="keab381.pdf"/>
              <related-article related-article-type="correction-forward" ext-link-type="doi" id="RA1" xlink:href="10.1093/rheumatology/keac326"/>
              <abstract>
                <title>Abstract</title>
                <sec id="s1">
                  <title>Objective</title>
                  <p>To evaluate the dose–response, efficacy and safety of dapirolizumab pegol (DZP) in
patients with SLE.</p>
                </sec>
                <sec id="s2">
                  <title>Methods</title>
                  <p>Adults with moderately to severely active SLE (SLEDAI-2K score ≥6 and ≥1 BILAG A or ≥2
BILAG B domain scores), receiving stable CS (≤40 mg/day prednisone-equivalent),
antimalarial or immunosuppressant drugs were included. Patients with stable LN
(proteinuria ≤2 g/day) not receiving high-dose CS or CYC were permitted entry.
Randomized patients received placebo or i.v. DZP (6/24/45 mg/kg) and standard-of-care
(SOC) treatment every 4 weeks to week 24, after which patients received only SOC to week
48. The primary objective was to establish a dose–response relationship based on week 24
BILAG-Based Composite Lupus Assessment (BICLA) responder rates.</p>
                </sec>
                <sec id="s3">
                  <title>Results</title>
                  <p>All DZP groups exhibited improvements in clinical and immunological outcomes
<italic toggle="yes">vs</italic> placebo at week 24; however, BICLA responder rates did not fit
pre-specified dose–response models [best-fitting model
(<italic toggle="yes">E</italic><sub>max</sub>): <italic toggle="yes">P</italic> = 0.07]. Incidences of serious
treatment-emergent adverse events across DZP groups were low and similar to placebo.
Following DZP withdrawal, SLEDAI-2K, physician’s global assessment (PGA), BILAG, and
Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) scores stabilized;
BICLA and SLE Responder Index (SRI-4) responder rates declined (likely due to
interventions with disallowed escape medications), BILAG flares increased, and
immunologic parameters returned towards baseline.</p>
                </sec>
                <sec id="s4">
                  <title>Conclusions</title>
                  <p>Although the primary objective was not met, DZP appeared to be well tolerated, and
patients exhibited improvements across multiple clinical and immunological measures of
disease activity after 24 weeks relative to placebo. The potential clinical benefit of
DZP warrants further investigation.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>systemic lupus erythematosus</kwd>
                <kwd>SLE</kwd>
                <kwd>lupus</kwd>
                <kwd>dapirolizumab pegol</kwd>
                <kwd>CD40 ligand</kwd>
              </kwd-group>
              <funding-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>UCB Pharma and Biogen Inc. Support</institution>
                    </institution-wrap>
                    <!-- oupReleaseDelayRemoved from OA Article (00|0) -->
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>Costello Medical Consulting</institution>
                    </institution-wrap>
                    <!-- oupReleaseDelayRemoved from OA Article (00|0) -->
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="11"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <boxed-text id="keab381-BOX1" position="float">
              <label>Rheumatology key messages</label>
              <list list-type="bullet">
                <list-item>
                  <p>Despite not meeting the primary objective (selecting a dose–response), dapirolizumab
pegol was well tolerated.</p>
                </list-item>
                <list-item>
                  <p>Improvements in disease activity (clinical and immunological) were observed after 24
weeks, <italic toggle="yes">vs</italic> placebo.</p>
                </list-item>
                <list-item>
                  <p>The potential clinical benefit of dapirolizumab pegol warrants further
investigation.</p>
                </list-item>
              </list>
            </boxed-text>
            <sec>
              <title>Introduction</title>
              <p>SLE, a chronic, multi-system autoimmune disease, is characterized by chronic inflammation
and the accrual of organ damage either from the disease itself or the medications used to
treat SLE [<xref rid="keab381-B1" ref-type="bibr">1–4</xref>]. The prevalence, which varies according to ethnicity [<xref rid="keab381-B5" ref-type="bibr">5</xref>], gender [<xref rid="keab381-B6" ref-type="bibr">6</xref>, <xref rid="keab381-B7" ref-type="bibr">7</xref>] and age [<xref rid="keab381-B8" ref-type="bibr">8</xref>], ranges from 30 to 100 cases per 100,000 people [<xref rid="keab381-B8" ref-type="bibr">8–13</xref>].</p>
              <p>Glucocorticoids, antimalarial drugs, and immunosuppressives have been the mainstay of SLE
therapy for several decades now [<xref rid="keab381-B14" ref-type="bibr">14</xref>].
However, long-term glucocorticoid therapy is associated with severe side effects, including
increased risk for infections, cardiovascular events, metabolic syndrome, cognitive
impairment, osteonecrosis, and osteoporosis [<xref rid="keab381-B15" ref-type="bibr">15</xref>, <xref rid="keab381-B16" ref-type="bibr">16</xref>]. With just one biologic,
the anti-BLyS mAb, belimumab, approved for the treatment of SLE, there remains a significant
unmet clinical need for additional treatment options [<xref rid="keab381-B17" ref-type="bibr">17</xref>, <xref rid="keab381-B18" ref-type="bibr">18</xref>].</p>
              <p>Interactions between CD40 ligand (CD40L, CD154; mainly expressed on activated T cells and
platelets) and the CD40 receptor (expressed on a variety of cells, including
antigen-presenting cells and B cells) play a key role in adaptive immune activation and
drive pathological processes in SLE, including B cell differentiation and proliferation
[<xref rid="keab381-B19" ref-type="bibr">19</xref>, <xref rid="keab381-B20" ref-type="bibr">20</xref>]. Inhibiting the interaction between CD40L and the CD40
receptor has been efficacious in animal models of several autoimmune diseases, including SLE
[<xref rid="keab381-B20" ref-type="bibr">20–24</xref>]. As such, CD40L has long been an attractive therapeutic target in human
SLE. However, early SLE studies with BG9588, an anti-CD40L antibody, were suspended due to
an increased rate of thromboembolic events [<xref rid="keab381-B25" ref-type="bibr">25</xref>]. This may have been a result of platelet activation and aggregation arising
from BG9588 fragment crystallizable (Fc)-mediated cross-linking [<xref rid="keab381-B26" ref-type="bibr">26</xref>].</p>
              <p>Nevertheless, CD40L remains a target of interest for SLE drug development given the
significant reduction of DNA antibody-forming cells observed with BG9588 in patients with LN
[<xref rid="keab381-B23" ref-type="bibr">23</xref>]. DZP, a polyethylene glycol-conjugated
antigen-binding (Fab′) fragment, which targets CD40L, but lacks a functional Fc domain, was
constructed to mitigate the potential for platelet activation and aggregation. DZP was shown
to have high affinity for CD40L in cell-based assays, with a dissociation constant
(K<sub>d</sub>) of 7.9 pM [<xref rid="keab381-B27" ref-type="bibr">27</xref>]. In a
preclinical study in rhesus macaques, histopathological data revealed no increase in
thromboembolic events upon administration of DZP compared with placebo, unlike the
widespread pulmonary thrombi that were previously observed with BG9588 [<xref rid="keab381-B27" ref-type="bibr">27</xref>].</p>
              <p>DZP has since been investigated in two phase 1 clinical studies. The first was a
double-blind, dose-escalation study (NCT01093911), in which healthy volunteers and patients
with SLE received single i.v. doses of DZP or placebo [<xref rid="keab381-B28" ref-type="bibr">28</xref>]. Rates of adverse events were comparable between the DZP and
placebo groups, and no thromboembolic events were reported [<xref rid="keab381-B28" ref-type="bibr">28</xref>]. The second study was a double-blind, placebo-controlled
study (NCT01764594), in which 24 patients with SLE received 30 mg/kg DZP i.v., followed by
15 mg/kg DZP every 2 weeks for a 10-week period [<xref rid="keab381-B29" ref-type="bibr">29</xref>]. Multiple doses of DZP were well-tolerated, and there were no thromboembolic
events during the study [<xref rid="keab381-B29" ref-type="bibr">29</xref>].</p>
              <p>Herein, we report outcomes from a phase 2b, placebo-controlled study of DZP in adult
patients with SLE (RISE; NCT02804763). The aims were to establish a dose–response
relationship, and evaluate the efficacy and safety of DZP compared with SOC treatment, and
to assess the durability of response following study drug withdrawal.</p>
            </sec>
            <sec>
              <title>Methods</title>
              <sec>
                <title>Patients</title>
                <p>Eligible patients were adults (aged ≥18 years) with SLE diagnosed by a physician and
confirmed using the SLICC classification criteria. Patients had one or more of the
following immunologic criteria (confirmed by the central laboratory): anti-dsDNA
antibodies (Farr assay); low complement (C3, C4 or both); and/or an ANA titre ≥1:80, in
combination with historical positivity for anti-dsDNA and/or positivity for anti-ENA
[anti-Smith antibody (anti-Sm), anti-SSA, anti-SSB or anti-RNP].</p>
                <p>Patients were recruited from Europe, Latin America, and North America between 2 June 2016
and 19 November 2018. Patients had moderate-to-severe disease activity determined by:
BILAG 2004 A score in one or more domain at screening or BILAG 2004 B scores in two or
more domains (if a BILAG 2004 A domain score was absent); SLEDAI-2K total score ≥6 at
screening, and a SLEDAI-2K score excluding points from laboratory values ≥4 at the
baseline visit. Patients were required to remain on stable doses of SOC medications [at
least 2 weeks prior to screening, 4 and 8 weeks prior to baseline for CS, antimalarials,
and immunosuppressants (e.g. AZA, MTX, MMF), respectively]. Antimalarial and
immunosuppressant doses could not be changed until week 24 unless toxicity or tolerability
issues arose. When a dose was increased due to worsening disease activity, the patient was
considered a nonresponder for the primary analysis.</p>
                <p>Exclusion criteria included pregnancy or breastfeeding; a history of malignancy (except
for treated cervical carcinoma <italic toggle="yes">in situ</italic>, basal cell carcinoma, or
dermatological squamous cell carcinoma); a clinically relevant, recurrent infection (three
or more times per year); and severe neuropsychiatric SLE, or other neurological symptoms
that might have prevented the patient from completing the required procedures and
assessments. Prior biologics were permitted provided that a wash-out period was undertaken
prior to screening (2- to 12-month wash-out, depending on the biologic).</p>
                <p>Patients with stable LN were permitted entry, excluding those with new or worsening
International Society of Nephrology/Renal Pathology Society class III or IV LN, or with
chronic kidney disease stage 3b (estimated glomerular filtration rate &lt;45 ml/min/1.73
m<sup>2</sup>, serum creatinine &gt;2.5 mg/dl, proteinuria &gt;2 g/day, or
protein:creatinine ratio &gt;226 mg/mmol).</p>
              </sec>
              <sec>
                <title>Ethics approval and consent for publication</title>
                <p>The study protocol, amendments, and patient informed consent were reviewed by a national,
regional, or Independent Ethics Committee or Institutional Review Board. This study was
conducted in accordance with the current version of the applicable regulatory and
International Council for Harmonisation-Good Clinical Practice requirements, the ethical
principles that have their origin in the principles of the declaration of Helsinki, and
the local laws of the countries involved. All the results presented in this article are in
aggregate form, and no personally identifiable information was used for this study.</p>
              </sec>
              <sec>
                <title>Study design</title>
                <p>This phase 2b study began with a 24-week, double-blind, placebo-controlled period, during
which patients received study drug and SOC. After the double-blind period, the study drug
was withdrawn, and patients were observed for 24 weeks during which they received only SOC
to evaluate the duration of the treatment effect (<xref rid="keab381-F1" ref-type="fig"><bold>Fig. 1</bold></xref>). Patients were randomized 1:1:1:1 via an interactive
voice/web response system to receive placebo or intravenous DZP at 6, 24, or 45 mg/kg (all
with concomitant SOC) every 4 weeks, up to and including week 20 (<xref rid="keab381-F1" ref-type="fig"><bold>Fig. 1</bold></xref>). Three dose levels of DZP were selected to
explore the dose–response relationship for DZP in SLE: 45 mg/kg every 4 weeks, as it was
determined to be the equivalent dose to that used in the initial dose repeating study
[<xref rid="keab381-B29" ref-type="bibr">29</xref>], 24 mg/kg, as it was expected to be
equivalent to the dose for which reduction in anti-dsDNA antibodies were observed in
previous studies [<xref rid="keab381-B25" ref-type="bibr">25</xref>], and 6 mg/kg, as this
was the lowest dose that showed an effect in preclinical analyses. The patient’s body
weight at baseline was used to determine the individual dose. Randomization was stratified
by CS dose at screening (≤10 mg/day or &gt;10 mg/day prednisone-equivalent).</p>
                <fig position="float" id="keab381-F1">
                  <label><sc>Fig</sc>. 1</label>
                  <caption>
                    <p>Study design</p>
                    <p><sup>a</sup>Patients stratified by CS dose ≤10 mg/day or &gt;10 mg/day prednisone
equivalent. CS: corticosteroids; DZP: dapirolizumab pegol; IV: intravenous; PBO:
placebo; Q4W: every 4 weeks; SOC: standard-of-care, including CS, immunosuppressants
and/or antimalarials.</p>
                  </caption>
                  <graphic xlink:href="keab381f1" position="float"/>
                </fig>
                <p>Patients receiving concomitant CS doses between 10–40 mg/day prednisone-equivalent were
required to initiate a protocol-specified taper 4 weeks after the first study drug
infusion (<xref rid="keab381-F1" ref-type="fig"><bold>Fig. 1</bold></xref>). The tapering
regimen aimed to reduce the daily dose to ≤7.5 mg/day by week 12, with no requirement to
reduce beyond this dose. Slower tapers were permitted. Patients who could not adhere to
the tapering regimen remained in the study and were not considered nonresponders for the
primary endpoint unless their CS dose exceeded the baseline prednisone-equivalent
dose.</p>
              </sec>
              <sec>
                <title>Primary efficacy endpoint</title>
                <p>The primary objective was to identify a dose–response relationship, based on the primary
efficacy variable of week 24 BICLA responder rates, across three doses of DZP and placebo,
simultaneously. Continuous dose–response models were evaluated in order to facilitate the
selection of suitable doses between those tested in the study that provided evidence of
efficacy. Four different dose–response models were selected to be tested using one-sided
Multiple Comparison Procedure-Modelling methodology [<xref rid="keab381-B30" ref-type="bibr">30</xref>] to control for multiplicity: a linear model, a logistic
model, and two <italic toggle="yes">E</italic><sub>max</sub> models (all for dose <italic toggle="yes">vs</italic>
BICLA response at week 24).</p>
                <p>BICLA response is defined as: (i) BILAG 2004 improvement without worsening (defined as
all BILAG A domain scores at baseline improved to B/C/D, all BILAG B domain scores at
baseline improved to C/D, no new BILAG A domain scores and no more than one new BILAG B
domain score compared with baseline); (ii) no worsening in SLEDAI-2K score compared with
baseline; (iii) no worsening in PGA compared with baseline (&lt;10 mm increase on a 100 mm
visual analogue scale); and (iv) no increase in concomitant SLE medications (no increase
or addition of immunosuppressant or antimalarial medication, and no increase in CS dose
over baseline).</p>
              </sec>
              <sec>
                <title>Secondary efficacy endpoints</title>
                <p>Secondary efficacy endpoints included the BICLA responder rate in individual dose groups
at week 24. Other secondary endpoints included SRI-4 response rates, changes from baseline
in SLEDAI-2K, PGA, CLASI scores, swollen and tender joint counts, cumulative number of
severe BILAG flares, and changes from baseline in immunologic parameters (anti-dsDNA and
aPL, and complement C3/C4 levels).</p>
                <p>Adverse events [AEs, including serious AEs (SAEs) and AEs of interest (AEOIs)] were
collected throughout the study. SAEs were defined as those that resulted in death or
inpatient hospitalization (or prolongation of existing hospitalization), were
life-threatening or medically important events, were congenital anomalies, or caused
persistent or significant disability. AEOIs, regardless of severity, were defined as
moderate-to-severe infections, infusion reactions, hypersensitivity reactions,
thromboembolic events, or prespecified neurological events. AEs were classified as
treatment-emergent (TEAEs) if the onset occurred at any time at or after the first
administration of study drug, and up to 12 weeks (84 days) after the last dose. All AEs
were coded using MedDRA version 19.1.</p>
              </sec>
              <sec>
                <title>Statistical analysis</title>
                <p>Based upon prior evidence in SLE, a placebo response rate of 25% was anticipated at week
24 [<xref rid="keab381-B31" ref-type="bibr">31–33</xref>]. A power
calculation determined that a total of 112 patients were required to complete the 24-week
double-blind period; this would provide 80% power of detecting a clinical effect of 29%
above placebo (one-sided type-1 error of 5% and equally-sized treatment groups).</p>
                <p>Efficacy outcomes were determined in the full analysis set, which comprised all patients
who received one or more full dose of study drug and had one or more post-baseline
efficacy measurement. All patients who received at least one dose (any dose) of study drug
were in the safety set, and safety and immunologic outcomes were analyzed.</p>
                <p>Immunologic outcomes are reported as the mean (<sc>s</sc>.<sc>d</sc>.) change from
baseline, or median (min–max) change from baseline if data are not normally distributed.
Efficacy outcomes are reported as the percentage of responders for binary outcomes
(BICLA/SRI-4 responder rates), or mean (<sc>s</sc>.<sc>d</sc>.) change from baseline for
continuous outcomes (SLEDAI-2K/PGA score). For continuous outcomes, baseline values were
included as covariates. Where <italic toggle="yes">P</italic>-values are reported, reference is made to
either odds ratios (BICLA/SRI-4 responder rate) or least squares mean differences
(SLEDAI-2K/PGA score) between DZP and placebo. These <italic toggle="yes">P</italic>-values were not
adjusted for multiplicity. Analyses of the primary efficacy variable are described in
detail in the <xref rid="sup1" ref-type="supplementary-material">Supplementary
Methods</xref>, available at <italic toggle="yes">Rheumatology</italic> online.</p>
              </sec>
            </sec>
            <sec>
              <title>Results</title>
              <sec>
                <title>Patient disposition and baseline characteristics</title>
                <p>Of 182 randomized patients, 178 (97.8%) completed the double-blind period, of whom 11
permanently discontinued study treatment prior to the end of the double-blind period.
Ninety percent of patients [164/182 (90.1%)] completed the observational period (<xref rid="sup1" ref-type="supplementary-material">supplementary Fig. S1</xref>, available at
<italic toggle="yes">Rheumatology</italic> online).</p>
                <p>Baseline demographics and clinical characteristics were similar across treatment groups.
All treatment groups were represented by a high proportion of White patients, though this
proportion was greater in the DZP 24 mg/kg group (<xref rid="keab381-T1" ref-type="table">Table 1</xref>). There was a slightly lower mean SLEDAI-2K score in the DZP 24 mg/kg
group, and a longer time to diagnosis in the DZP 45 mg/kg group (<xref rid="keab381-T1" ref-type="table">Table 1</xref>). Mucocutaneous and musculoskeletal BILAG domains were
the predominant domains that were present at baseline in this patient population (<xref rid="sup1" ref-type="supplementary-material">supplementary Table S1</xref>, available at
<italic toggle="yes">Rheumatology</italic> online). More than half of the patients had baseline CS
doses ≥10 mg/day; less than one-quarter of patients had baseline doses ≥20 mg/day (<xref rid="keab381-T1" ref-type="table">Table 1</xref>). Across all groups, the majority of
patients were able to taper their CS doses to ≤7.5 mg/day by week 24 (83.7, 86.0, 79.5,
and 80.4% of the placebo and DZP 6, 24, and 45 mg/kg groups, respectively).</p>
                <table-wrap position="float" id="keab381-T1">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline demographics and clinical characteristics</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="char" char="(" span="1"/>
                      <col valign="top" align="char" char="(" span="1"/>
                      <col valign="top" align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1">Mean (<sc>s</sc>.<sc>d</sc>.), unless otherwise stated</th>
                        <th rowspan="1" colspan="1">SOC + PBO (<italic toggle="yes">n</italic> = 43)</th>
                        <th rowspan="1" colspan="1">SOC + DZP 6 mg/kg (<italic toggle="yes">n</italic> = 43)</th>
                        <th rowspan="1" colspan="1">SOC + DZP 24 mg/kg (<italic toggle="yes">n</italic> = 44)</th>
                        <th rowspan="1" colspan="1">SOC + DZP 45 mg/kg (<italic toggle="yes">n</italic> = 46)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Demographics</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Age, years, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">42.7 (12.5)</td>
                        <td rowspan="1" colspan="1">40.5 (11.7)</td>
                        <td rowspan="1" colspan="1">42.6 (10.5)</td>
                        <td rowspan="1" colspan="1">39.0 (13.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Female, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">39 (90.7)</td>
                        <td rowspan="1" colspan="1">40 (93.0)</td>
                        <td rowspan="1" colspan="1">39 (88.6)</td>
                        <td rowspan="1" colspan="1">42 (91.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> BMI, kg/m<sup>2</sup>, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">25.6 (4.2)</td>
                        <td rowspan="1" colspan="1">26.1 (5.0)</td>
                        <td rowspan="1" colspan="1">26.0 (4.4)</td>
                        <td rowspan="1" colspan="1">25.3 (4.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Racial group, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> American Indian/Alaskan native</td>
                        <td rowspan="1" colspan="1">2 (4.7)</td>
                        <td rowspan="1" colspan="1">1 (2.3)</td>
                        <td rowspan="1" colspan="1">1 (2.3)</td>
                        <td rowspan="1" colspan="1">1 (2.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Asian</td>
                        <td rowspan="1" colspan="1">1 (2.3)</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">1 (2.3)</td>
                        <td rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Black</td>
                        <td rowspan="1" colspan="1">1 (2.3)</td>
                        <td rowspan="1" colspan="1">4 (9.3)</td>
                        <td rowspan="1" colspan="1">1 (2.3)</td>
                        <td rowspan="1" colspan="1">5 (10.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> White</td>
                        <td rowspan="1" colspan="1">25 (58.1)</td>
                        <td rowspan="1" colspan="1">24 (55.8)</td>
                        <td rowspan="1" colspan="1">32 (72.7)</td>
                        <td rowspan="1" colspan="1">27 (58.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Other/mixed</td>
                        <td rowspan="1" colspan="1">14 (32.6)</td>
                        <td rowspan="1" colspan="1">14 (32.6)</td>
                        <td rowspan="1" colspan="1">9 (20.5)</td>
                        <td rowspan="1" colspan="1">13 (28.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Clinical characteristics</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Time since diagnosis, years,  median (min–max)</td>
                        <td rowspan="1" colspan="1">5.4 (0.1–30.0)</td>
                        <td rowspan="1" colspan="1">5.0 (0.2–27.8)</td>
                        <td rowspan="1" colspan="1">5.1 (0.3–27.0)</td>
                        <td rowspan="1" colspan="1">8.2 (0.3–25.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> BILAG 2004 total score, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">18.6 (3.7)</td>
                        <td rowspan="1" colspan="1">19.1 (4.1)</td>
                        <td rowspan="1" colspan="1">18.6 (3.9)</td>
                        <td rowspan="1" colspan="1">19.8 (5.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> SLEDAI-2K total score<sup>a</sup>, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">10.7 (3.4)</td>
                        <td rowspan="1" colspan="1">11.4 (2.4)</td>
                        <td rowspan="1" colspan="1">9.9 (2.5)</td>
                        <td rowspan="1" colspan="1">11.1 (3.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> CLASI activity score, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">7.8 (6.1)</td>
                        <td rowspan="1" colspan="1">7.5 (6.2)</td>
                        <td rowspan="1" colspan="1">7.0 (6.4)</td>
                        <td rowspan="1" colspan="1">8.6 (6.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Swollen joint count, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">7.7 (5.9)</td>
                        <td rowspan="1" colspan="1">7.9 (5.4)</td>
                        <td rowspan="1" colspan="1">6.0 (4.7)</td>
                        <td rowspan="1" colspan="1">6.7 (4.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Tender joint count, mean (<sc>s</sc>.<sc>d</sc>.),
(<italic toggle="yes">n</italic>)<sup>b</sup></td>
                        <td rowspan="1" colspan="1">9.3 (5.9) (<italic toggle="yes">n</italic> = 41)</td>
                        <td rowspan="1" colspan="1">9.7 (6.3) (<italic toggle="yes">n</italic> = 43)</td>
                        <td rowspan="1" colspan="1">9.1 (5.6) (<italic toggle="yes">n</italic> = 41)</td>
                        <td rowspan="1" colspan="1">10.7 (7.2) (<italic toggle="yes">n</italic> = 44)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> ANA ≥1:80, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">43 (100.0)</td>
                        <td rowspan="1" colspan="1">41 (95.3)</td>
                        <td rowspan="1" colspan="1">42 (95.5)</td>
                        <td rowspan="1" colspan="1">41 (89.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Anti-dsDNA &gt;10 IU, <italic toggle="yes">n</italic> (%)<sup>c</sup></td>
                        <td rowspan="1" colspan="1">17 (39.5)</td>
                        <td rowspan="1" colspan="1">24 (55.8)</td>
                        <td rowspan="1" colspan="1">18 (40.9)</td>
                        <td rowspan="1" colspan="1">21 (45.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Low C3 or C4, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">23 (53.5)</td>
                        <td rowspan="1" colspan="1">25 (58.1)</td>
                        <td rowspan="1" colspan="1">26 (59.1)</td>
                        <td rowspan="1" colspan="1">26 (56.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Medications at baseline</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> CS at baseline, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">38 (88.4)</td>
                        <td rowspan="1" colspan="1">40 (93.0)</td>
                        <td rowspan="1" colspan="1">39 (88.6)</td>
                        <td rowspan="1" colspan="1">36 (78.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  Dose at baseline, mg/day,   median (min–max)</td>
                        <td rowspan="1" colspan="1">10.0 (0.0–40.0)</td>
                        <td rowspan="1" colspan="1">10.0 (0.0–25.0)</td>
                        <td rowspan="1" colspan="1">10.0 (0.0–20.0)</td>
                        <td rowspan="1" colspan="1">10.0 (0.0–30.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  ≥10 mg/day, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">27 (62.8)</td>
                        <td rowspan="1" colspan="1">28 (65.1)</td>
                        <td rowspan="1" colspan="1">24 (54.5)</td>
                        <td rowspan="1" colspan="1">24 (52.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  ≥20 mg/day, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">10 (23.3)</td>
                        <td rowspan="1" colspan="1">6 (14.0)</td>
                        <td rowspan="1" colspan="1">4 (9.1)</td>
                        <td rowspan="1" colspan="1">8 (17.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Immunosuppressants, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">22 (51.2)</td>
                        <td rowspan="1" colspan="1">25 (58.1)</td>
                        <td rowspan="1" colspan="1">25 (56.8)</td>
                        <td rowspan="1" colspan="1">26 (56.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> SLE-related immunosuppressants, <italic toggle="yes">n</italic> (%)<sup>d</sup></td>
                        <td rowspan="1" colspan="1">22 (48.9)</td>
                        <td rowspan="1" colspan="1">25 (55.6)</td>
                        <td rowspan="1" colspan="1">25 (55.6)</td>
                        <td rowspan="1" colspan="1">26 (55.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  AZA, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">14 (31.1)</td>
                        <td rowspan="1" colspan="1">9 (20.0)</td>
                        <td rowspan="1" colspan="1">15 (33.3)</td>
                        <td rowspan="1" colspan="1">12 (25.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  MTX, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">6 (13.3)</td>
                        <td rowspan="1" colspan="1">11 (24.4)</td>
                        <td rowspan="1" colspan="1">6 (13.3)</td>
                        <td rowspan="1" colspan="1">7 (14.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  MTX sodium, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">1 (2.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  MMF, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">2 (4.4)</td>
                        <td rowspan="1" colspan="1">6 (13.3)</td>
                        <td rowspan="1" colspan="1">5 (11.1)</td>
                        <td rowspan="1" colspan="1">7 (14.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  Mycophenolate sodium, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">1 (2.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  LEF, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">1 (2.2)</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Antimalarials, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">29 (67.4)</td>
                        <td rowspan="1" colspan="1">30 (69.8)</td>
                        <td rowspan="1" colspan="1">33 (75.0)</td>
                        <td rowspan="1" colspan="1">28 (60.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Prior SLE-related medications<sup>d,e</sup></td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> CS, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">20 (44.4)</td>
                        <td rowspan="1" colspan="1">27 (60.0)</td>
                        <td rowspan="1" colspan="1">20 (44.4)</td>
                        <td rowspan="1" colspan="1">24 (51.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Immunosuppressants, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">12 (26.7)</td>
                        <td rowspan="1" colspan="1">21 (46.7)</td>
                        <td rowspan="1" colspan="1">11 (24.4)</td>
                        <td rowspan="1" colspan="1">12 (25.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  AZA, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">2 (4.4)</td>
                        <td rowspan="1" colspan="1">6 (13.3)</td>
                        <td rowspan="1" colspan="1">3 (6.7)</td>
                        <td rowspan="1" colspan="1">5 (10.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  MMF, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">3 (6.7)</td>
                        <td rowspan="1" colspan="1">6 (13.3)</td>
                        <td rowspan="1" colspan="1">3 (6.7)</td>
                        <td rowspan="1" colspan="1">1 (2.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  Belimumab, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">5 (11.1)</td>
                        <td rowspan="1" colspan="1">4 (8.9)</td>
                        <td rowspan="1" colspan="1">1 (2.2)</td>
                        <td rowspan="1" colspan="1">1 (2.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  MTX, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">1 (2.2)</td>
                        <td rowspan="1" colspan="1">5 (11.1)</td>
                        <td rowspan="1" colspan="1">3 (6.7)</td>
                        <td rowspan="1" colspan="1">2 (4.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  Anifrolumab, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">1 (2.2)</td>
                        <td rowspan="1" colspan="1">4 (8.9)</td>
                        <td rowspan="1" colspan="1">1 (2.2)</td>
                        <td rowspan="1" colspan="1">2 (4.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  Blisibimod, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">1 (2.2)</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">1 (2.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  Mycophenolate sodium, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">2 (4.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  Ustekinumab, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">1 (2.2)</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">1 (2.2)</td>
                        <td rowspan="1" colspan="1">1 (2.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  MTX sodium, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">1 (2.2)</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  Lulizumab pegol, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">1 (2.2)</td>
                        <td rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Antiprotozoals, <italic toggle="yes">n</italic> (%)<sup>f</sup></td>
                        <td rowspan="1" colspan="1">4 (8.9)</td>
                        <td rowspan="1" colspan="1">9 (20.0)</td>
                        <td rowspan="1" colspan="1">4 (8.9)</td>
                        <td rowspan="1" colspan="1">9 (19.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> mAbs, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">4 (8.9)</td>
                        <td rowspan="1" colspan="1">4 (8.9)</td>
                        <td rowspan="1" colspan="1">3 (6.7)</td>
                        <td rowspan="1" colspan="1">4 (8.5)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn1">
                      <p>Full analysis set, unless otherwise stated. <sup>a</sup>SLEDAI-2K total score
calculated using anti-dsDNA positive if &gt;10 IU; <sup>b</sup>subjects had
arthritis at baseline; <sup>c</sup>Farr assay; <sup>d</sup>data shown for the safety
set; <sup>e</sup>a prior medication is any medication with an end date and time
before the date of first administration of the study drug; <sup>f</sup>including
antimalarials. Combinations of immunosuppressants with antimalarials and/or CS are
listed in <xref rid="sup1" ref-type="supplementary-material">supplementary Table
S5</xref>, available at <italic toggle="yes">Rheumatology</italic> online. ANA: anti-nuclear
antibody; AZA: azathioprine; BILAG: British Isles Lupus Assessment Group; BMI: body
mass index; C3/C4: complement C3/C4; CLASI: Cutaneous Lupus Erythematosus Disease
Area and Severity Index; CS: corticosteroids; dsDNA: double-stranded DNA; DZP:
dapirolizumab pegol; IU: International Units; LEF: leflunomide; mAb: monoclonal
antibody; MMF: mycophenolate mofetil; MTX: methotrexate; PBO: placebo; S.D.:
standard deviation; SLE: systemic lupus erythematosus; SLEDAI-2K: Systemic Lupus
Erythematosus Disease Activity Index 2000; SOC: standard-of-care.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec>
                <title>Clinical and immunologic outcomes (double-blind period)</title>
                <p>As no pre-specified dose–response relationship model fit the observed BICLA response
rates at week 24 with statistical significance [best-fitting model
(<italic toggle="yes">E</italic><sub>max</sub>): <italic toggle="yes">P</italic> = 0.07], the primary endpoint was
not met (<xref rid="sup1" ref-type="supplementary-material">supplementary Fig. S2</xref>,
available at <italic toggle="yes">Rheumatology</italic> online). The study was stratified for baseline
CS dose, but this was not found to be a significant factor in this study. It was, however,
kept in all relevant planned models as a covariate.</p>
                <p>Clinical measures of disease activity, including BICLA, SRI-4, SLEDAI-2K, PGA, and BILAG
total scores, generally improved from baseline in DZP-treated patients <italic toggle="yes">vs</italic>
placebo (<xref rid="keab381-F2" ref-type="fig">Fig. 2A–E</xref>). Moreover, the cumulative
numbers of BILAG severe flares at week 24 were numerically lower in patients treated with
DZP 6, 24, or 45 mg/kg (4, 0, and 1, respectively) compared with placebo (7) (<xref rid="keab381-F2" ref-type="fig">Fig. 2F</xref>). Additionally, greater improvements from
baseline in CLASI activity scores were observed in DZP-treated patients
<italic toggle="yes">vs</italic> placebo (<xref rid="sup1" ref-type="supplementary-material">supplementary Table S2</xref>, available at <italic toggle="yes">Rheumatology</italic> online).</p>
                <fig position="float" id="keab381-F2">
                  <label><sc>Fig</sc>. 2</label>
                  <caption>
                    <p> Clinical outcomes. (<bold>A</bold>) BICLA<sup>a</sup> and (<bold>B</bold>)
SRI-4<sup>a</sup> responder rates, change from baseline in (<bold>C</bold>)
SLEDAI-2K<sup>b</sup>, (<bold>D</bold>) PGA<sup>b</sup> and (<bold>E</bold>) BILAG
2004 total score<sup>c</sup>, and (<bold>F</bold>) cumulative number of severe BILAG
flares<sup>d</sup></p>
                    <p>*<italic toggle="yes">P</italic> &lt; 0.05 for the odds ratio between DZP and PBO (A and B), or
for the least squares mean differences between DZP and PBO (C, D, and E).
<sup>a</sup>Full analysis set, modified nonresponder imputation using logistic
regression; <sup>b</sup>Completer set, observed case using mixed model with repeated
measures; <sup>c</sup>Full analysis set, observed cases using ANCOVA; <sup>d</sup>Full
analysis set, observed case, BILAG severe flare: new Grade A since the previous visit.
Multiple flares that may have occurred in a single patient were recorded separately.
BICLA: BILAG-Based Composite Lupus Assessment; BILAG: British Isles Lupus Assessment;
DZP: dapirolizumab pegol; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity
Index 2000; SRI-4: SLE Responder Index; PBO: placebo; PGA: physician’s global
assessment; SOC: standard-of-care.</p>
                  </caption>
                  <graphic xlink:href="keab381f2" position="float"/>
                </fig>
                <p>Compared with placebo, DZP-treated patients had greater reductions from baseline in
anti-dsDNA levels and greater increases from baseline in C3 and C4 levels throughout the
double-blind period (<xref rid="keab381-F3" ref-type="fig">Fig. 3</xref>). Of the patients
with either low C3 or C4 levels at baseline, more DZP-treated patients achieved normal
levels by week 24 [16/27 (59.3%), 19/27 (70.4%), and 12/26 (46.2%) of the DZP 6, 24, and
45 mg/kg groups, respectively], compared with placebo-treated patients [9/24 (37.5%)].
Levels of IgG and IgM beta-2 glycoprotein I and aCL also declined to a greater extent in
DZP-treated patients with elevated baseline levels (<xref rid="sup1" ref-type="supplementary-material">supplementary Table S2</xref>, available at
<italic toggle="yes">Rheumatology</italic> online).</p>
                <fig position="float" id="keab381-F3">
                  <label><sc>Fig</sc>. 3</label>
                  <caption>
                    <p>Immunologic outcomes. Change from baseline in (<bold>A</bold>)
Anti-dsDNA<sup>a</sup>, (<bold>B</bold>) Complement C3<sup>b</sup>, and
(<bold>C</bold>) Complement C4<sup>c</sup></p>
                    <p>Safety set. <sup>a</sup>In patients with &lt;10 IU at baseline (measured using the
Farr assay); <sup>b</sup>in patients with complement C3 &lt;LLN at baseline;
<sup>c</sup>in patients with complement C4 &lt;LLN at baseline. dsDNA:
double-stranded DNA (Farr assay); DZP: dapirolizumab pegol; IU: international units;
LLN: lower limit of normal; PBO: placebo; SOC: standard of care.</p>
                  </caption>
                  <graphic xlink:href="keab381f3" position="float"/>
                </fig>
              </sec>
              <sec>
                <title>Clinical and immunologic outcomes (observational period)</title>
                <p>Following study drug withdrawal, 5, 8, 5, and 4 severe BILAG flares occurred in the
placebo and DZP 6, 24, and 45 mg/kg groups, respectively, compared with 7, 4, 0, and 1
severe flares that occurred in the placebo and DZP 6, 24, and 45 mg/kg groups,
respectively, during the double-blind period. However, the cumulative total number of
flares (12, 12, 5, and 5 in the placebo and DZP 6, 24, and 45 mg/kg groups, respectively)
that occurred during the 48-week study period was higher in the placebo and DZP 6 mg/kg
groups than in the DZP 24 and 45 mg/kg groups (<xref rid="keab381-F2" ref-type="fig">Fig.
2F</xref>). SLEDAI-2K, PGA and BILAG total scores stabilized across treatment groups
after study drug withdrawal, whereas BICLA and SRI-4 response rates were generally lower
at week 48 than at week 24 in all groups <bold>(</bold><xref rid="keab381-F2" ref-type="fig">Fig. 2A–E</xref>). For BICLA, the reductions ranged from 11.6 to 18.1%
across DZP groups, and in the placebo group, the decrease was 11.6%. For SRI-4, the
decline ranged from 9.1 to 13.9% across DZP groups and was 14.0% in the placebo group
<bold>(</bold><xref rid="keab381-F2" ref-type="fig">Fig. 2A and B</xref>). The decreases
in BICLA and SRI-4 response rates were most often due to interventions with escape
medicines during this period, which per protocol led to nonresponder classification. This
was the case in 7 (16.3%), 14 (32.6%), 14 (31.8%), and 11 (23.9%) of the placebo and DZP
6, 24, and 45 mg/kg groups, respectively (<xref rid="sup1" ref-type="supplementary-material">supplementary Table S3</xref>, available at <italic toggle="yes">Rheumatology</italic>
online). Following study drug withdrawal, serologies generally worsened and returned
towards baseline (<xref rid="keab381-F3" ref-type="fig">Fig. 3</xref><bold>;</bold><xref rid="sup1" ref-type="supplementary-material">supplementary Table S2</xref>, available at
<italic toggle="yes">Rheumatology</italic> online).</p>
              </sec>
              <sec>
                <title>Safety</title>
                <p>There was a higher incidence of TEAEs in the treatment groups compared with placebo, and
a greater number of severe TEAES occurred in the DZP 45 mg/kg group than in other groups;
however, serious TEAEs were generally low and similar across treatment groups (<xref rid="keab381-T2" ref-type="table">Table 2</xref>). In addition, the incidence of TEAEs
related to abnormal laboratory values was low and similar across treatment groups, and no
safety concerns for abnormal vital signs or ECG findings associated with DZP were
identified (data not shown). Rates of infection (particularly upper respiratory tract
infections) were greater among DZP-treated patients <italic toggle="yes">vs</italic> placebo (<xref rid="keab381-T2" ref-type="table">Table 2</xref>). Herpes zoster infections occurred in
the DZP 6 mg/kg group more than in other groups; however, the incidence of herpes zoster
infection overall was low and similar across treatment groups. Most of the upper
respiratory tract infections were mild or moderate in intensity, and none led to
discontinuations of the study drug. One bacteraemia caused by <italic toggle="yes">Pseudomonas</italic>
infection in the DZP 24 mg/kg group led to permanent discontinuation of study drug. Four
thromboembolic TEAEs were observed during the double-blind period: three in the placebo
group and one in a patient receiving DZP 24 mg/kg (<xref rid="sup1" ref-type="supplementary-material">supplementary Table S4</xref>, available at <italic toggle="yes">Rheumatology</italic>
online).</p>
                <table-wrap position="float" id="keab381-T2">
                  <label>Table 2</label>
                  <caption>
                    <p>Safety outcomes in the double-blind treatment period (safety set)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%)</th>
                        <th rowspan="1" colspan="1">SOC + PBO (<italic toggle="yes">n</italic> = 45)</th>
                        <th rowspan="1" colspan="1">SOC + DZP 6 mg/kg (<italic toggle="yes">n</italic> = 45)</th>
                        <th rowspan="1" colspan="1">SOC + DZP 24 mg/kg (<italic toggle="yes">n</italic> = 45)</th>
                        <th rowspan="1" colspan="1">SOC + DZP 45 mg/kg (<italic toggle="yes">n</italic> = 47)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">
                          <bold>Mean (<sc>s</sc>.<sc>d</sc>.) duration of exposure (days)</bold>
                        </td>
                        <td rowspan="1" colspan="1">
                          <bold>216.7 (27.0)</bold>
                        </td>
                        <td rowspan="1" colspan="1">
                          <bold>224.0 (4.7)</bold>
                        </td>
                        <td rowspan="1" colspan="1">
                          <bold>215.6 (29.6)</bold>
                        </td>
                        <td rowspan="1" colspan="1">
                          <bold>212.1 (38.5)</bold>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Any TEAE<xref rid="tblfn2" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td rowspan="1" colspan="1">28 (62.2) [90]</td>
                        <td rowspan="1" colspan="1">29 (64.4) [130]</td>
                        <td rowspan="1" colspan="1">35 (77.8) [116]</td>
                        <td rowspan="1" colspan="1">34 (72.3) [84]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Infections and infestations<xref rid="tblfn2" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td rowspan="1" colspan="1">15 (33.3) [21]</td>
                        <td rowspan="1" colspan="1">21 (46.7) [43]</td>
                        <td rowspan="1" colspan="1">26 (57.8) [40]</td>
                        <td rowspan="1" colspan="1">22 (46.8) [29]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  Mild</td>
                        <td rowspan="1" colspan="1">9 (20.0)</td>
                        <td rowspan="1" colspan="1">10 (22.2)</td>
                        <td rowspan="1" colspan="1">12 (26.7)</td>
                        <td rowspan="1" colspan="1">13 (27.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  Moderate</td>
                        <td rowspan="1" colspan="1">5 (11.1)</td>
                        <td rowspan="1" colspan="1">11 (24.4)</td>
                        <td rowspan="1" colspan="1">13 (28.9)</td>
                        <td rowspan="1" colspan="1">6 (12.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  Severe</td>
                        <td rowspan="1" colspan="1">1 (2.2)</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">1 (2.2)</td>
                        <td rowspan="1" colspan="1">3 (6.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  Herpes viral infections<xref rid="tblfn2" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td rowspan="1" colspan="1">1 (2.2) [1]</td>
                        <td rowspan="1" colspan="1">5 (11.1) [5]</td>
                        <td rowspan="1" colspan="1">2 (4.4) [2]</td>
                        <td rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">   Herpes zoster<xref rid="tblfn2" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td rowspan="1" colspan="1">1 (2.2) [1]</td>
                        <td rowspan="1" colspan="1">3 (6.7) [3]</td>
                        <td rowspan="1" colspan="1">2 (4.4) [2]</td>
                        <td rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">   Oral herpes<xref rid="tblfn2" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">2 (4.4) [2]</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Upper respiratory tract infections<xref rid="tblfn2" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td rowspan="1" colspan="1">6 (13.3) [8]</td>
                        <td rowspan="1" colspan="1">12 (26.7) [14]</td>
                        <td rowspan="1" colspan="1">15 (33.3) [20]</td>
                        <td rowspan="1" colspan="1">13 (27.7) [15]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Infusion reactions<xref rid="tblfn2" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">1 (2.1) [1]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Thromboembolic events</td>
                        <td rowspan="1" colspan="1">3 (6.7)</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">1 (2.2)</td>
                        <td rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">TEAEs of interest<xref rid="tblfn2" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td rowspan="1" colspan="1">9 (20.0) [11]</td>
                        <td rowspan="1" colspan="1">11 (24.4) [18]</td>
                        <td rowspan="1" colspan="1">13 (28.9) [18]</td>
                        <td rowspan="1" colspan="1">10 (21.3) [12]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Serious TEAEs<xref rid="tblfn2" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td rowspan="1" colspan="1">5 (11.1) [6]</td>
                        <td rowspan="1" colspan="1">2 (4.4) [2]</td>
                        <td rowspan="1" colspan="1">4 (8.9) [4]</td>
                        <td rowspan="1" colspan="1">5 (10.6) [6]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Study discontinuation due to TEAEs<xref rid="tblfn2" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td rowspan="1" colspan="1">1 (2.2) [1]</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Permanent withdrawal of study drug due to TEAEs<xref rid="tblfn2" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td rowspan="1" colspan="1">4 (8.9) [4]</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">2 (4.4) [2]</td>
                        <td rowspan="1" colspan="1">2 (4.3) [2]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Severe TEAEs<xref rid="tblfn2" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td rowspan="1" colspan="1">3 (6.7) [4]</td>
                        <td rowspan="1" colspan="1">1 (2.2) [1]</td>
                        <td rowspan="1" colspan="1">3 (6.7) [3]</td>
                        <td rowspan="1" colspan="1">7 (14.9) [8]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Deaths</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn2">
                      <label>a</label>
                      <p>Data presented as <italic toggle="yes">n</italic> (%) [ER per 100 patient-years]. TEAEs were
those with onset at the time of, or after, the first dose of study drug, until
12 weeks after the last dose. Patients who withdrew from the study early (during the
double-blind treatment period) entered a safety follow-up period, which ended
12 weeks after the final dose of study drug. DZP: dapirolizumab pegol; ER: event
rate; PBO: placebo; TEAE: treatment-emergent adverse event; S.D.: standard
deviation; SOC: standard of care.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
            </sec>
            <sec>
              <title>Discussion</title>
              <p>The aim of this phase 2b double-blind placebo-controlled trial was to establish a
dose–response relationship and evaluate the efficacy and safety of DZP in patients with
active SLE compared with SOC treatment. This study also assessed the durability of response
following study drug withdrawal through a biphasic study design, in which patients received
double-blind treatment with DZP or placebo (and SOC) for 24 weeks, followed by a 24-week
observational period during which patients received SOC only. The decision to withdraw study
drug at week 24 and incorporate an observational follow-up period was based on research in
animal transplant models that reported sustained responses even after withdrawal of CD40L
antagonist [<xref rid="keab381-B24" ref-type="bibr">24</xref>].</p>
              <p>Multiple Comparison Procedure-Modelling methodology was used to assess the dose–response
relationship of DZP based on week 24 BICLA responder rates (the primary efficacy variable).
Continuous dose–response models were selected as these can facilitate the selection of
suitable doses between those that demonstrate efficacy in the study. Since the BICLA
responder rates at week 24 did not fit any of the pre-specified dose–response models with
statistical significance [best-fitting model (<italic toggle="yes">E</italic><sub>max</sub>):
<italic toggle="yes">P</italic> = 0.07], the primary objective was not met. DZP-treated patients did
show consistent numerical improvements across multiple clinical measures of disease
activity; however, as these were not part of the primary endpoint it is not appropriate to
discuss the significance of these outcomes as the study was not designed or powered to
determine this. Furthermore, DZP treatment resulted in improvements relative to placebo
across multiple pharmacodynamic biomarkers, indicating a biologic effect.</p>
              <p>Upon withdrawal of DZP, immunologic parameters generally worsened and returned to baseline
levels, providing further evidence of DZP biologic activity, but challenging the capacity of
DZP to induce tolerance. While BILAG, SLEDAI, and PGA scores stabilized across treatment
groups, BICLA and SRI-4 response rates declined. This was most likely due to interventions
with escape medicines used during this period, which automatically led to nonresponder
classification.</p>
              <p>DZP appeared to have an acceptable safety profile and was generally well tolerated. The
risk of thromboembolic events in the anti-CD40L drug class should be acknowledged and while
a total of four thromboembolic events were reported during the double-blind period, three
occurred in patients receiving placebo. For one DZP-treated patient (24 mg/kg) a deep vein
thrombosis of the left upper extremity (subclavian axillary, associated with a peripherally
inserted central catheter line inserted for antibiotic treatment due to cellulitis) was
reported, which started 74 days after the last infusion of DZP, and was deemed unrelated to
the study drug. The findings indicate that DZP treatment may provide a smaller risk of
thromboembolism in comparison with other anti-CD40L treatments. These outcomes are similar
to those of preclinical and phase 1 DZP studies, which revealed low rates of thromboembolic
events during DZP treatment compared with placebo [<xref rid="keab381-B27" ref-type="bibr">27–29</xref>].</p>
              <p>Although the present study was limited by its relatively short duration and the small
sample size, which prevented analyses being conducted within specific racial groups, high
retention rates were observed (&gt;95% for the 24-week double-blind period and &gt;90% for
the full 48-week study). As a consequence of high retention rates, missing data imputation
was minimized. Therefore, these results are highly representative of the study population as
estimation bias is reduced. The positive results from this study are also limited by the
failure to meet the primary endpoint. This should be recognized as such but highlights the
need for future studies of DZP to demonstrate the efficacy and safety of DZP within a larger
study population and for a longer duration, using carefully selected endpoints.</p>
              <p>Treatment options for SLE are limited at the time of publication, with only one biologic,
belimumab, approved by regulatory authorities for the treatment of SLE [<xref rid="keab381-B34" ref-type="bibr">34</xref>, <xref rid="keab381-B35" ref-type="bibr">35</xref>], while many others have failed in clinical development [<xref rid="keab381-B17" ref-type="bibr">17</xref>, <xref rid="keab381-B18" ref-type="bibr">18</xref>].
Glucocorticoids are frequently used for their potent anti-inflammatory and immunosuppressive
properties, but their chronic use is associated with severe adverse events [<xref rid="keab381-B16" ref-type="bibr">16</xref>]. As such, there is a need to widen the
biologic repertoire available for the treatment of SLE patients to reduce disease activity,
prevent flares, and restrict accrual of organ damage.</p>
              <p>These data indicate DZP may be efficacious, with an acceptable safety profile, in adult
patients with moderately to severely active SLE. The potential clinical benefit of DZP
warrants further investigation in a larger study.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="sup1" position="float" content-type="local-data">
                <label>keab381_Supplementary_Data</label>
                <media xlink:href="keab381_supplementary_data.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="ack1">
              <title>Acknowledgements</title>
              <p>The authors thank the patients, the investigators and their teams who took part in this
study. The authors also acknowledge Jacob Boyle and JoAnn Gorden, for data and statistical
programming; Simone Emanuele Auteri, PhD (UCB Pharma, Brussels, Belgium) for publication
coordination; and Sam Fraser, PhD and Alyssa McVey, PhD (Costello Medical, Cambridge, UK)
for medical writing and editorial assistance based on the authors’ input and direction.
I.N.B. is a National Institute for Health Research (NIHR) Senior Investigator and is funded
by Versus Arthritis and the NIHR Manchester Biomedical Research Centre; the views expressed
in this publication are those of the author(s) and not necessarily those of the NHS, the
NIHR or the Department of Health. This study was funded by UCB Pharma and Biogen Inc.
Substantial contributions to study conception and design were made by R.A.F., I.N.B., T.D.,
M.G.L., P.L., M.U., B.H., T.J., C.Brittain, J.L., C.Barbey and C.S.; substantial
contributions to analysis and interpretation of the data were made by R.A.F., I.N.B., T.D.,
M.G.L., P.L., M.U., B.H., T.J., C.Brittain, J.L., C.Barbey and C.S.; drafting the article or
revising it critically for important intellectual content was carried out by R.A.F., I.N.B.,
T.D., M.G.L., P.L., M.U., B.H., T.J., C.Brittain, J.L., C.Barbey and C.S.; and final
approval of the version of the article to be published was given by R.A.F., I.N.B., T.D.,
M.G.L., P.L., M.U., B.H., T.J., C.Brittain, J.L., C.Barbey and C.S.</p>
              <p><italic toggle="yes">Funding</italic>: This work was supported by UCB Pharma and Biogen Inc. Support for
third-party writing assistance for this article, provided by Costello Medical Consulting,
was funded by UCB Pharma in accordance with Good Publication Practice (GPP3) guidelines
(<ext-link xlink:href="http://www.ismpp.org/gpp3" ext-link-type="uri">http://www.ismpp.org/gpp3</ext-link>).</p>
              <p><italic toggle="yes">Disclosure statement:</italic> R.A.F. received research grants to conduct this
study, and has received consulting fees from UCB Pharma and Biogen; I.N.B. received
consulting fees from UCB Pharma, Astra Zeneca, Merck Serono and Eli Lilly, and has received
grants from Genzyme Sanofi and GlaxoSmithKline; T.D. received research grants to conduct
this study, and has received consulting fees from UCB Pharma; M.G.L. and P.L., none
declared; M.U. is Chair of the Data Safety Monitoring Committee; B.H., T.J., C.Brittain and
C.S. are employees and stockholders of UCB Pharma; J.L. and C.Barbey are employees and
stockholders of Biogen.</p>
              <sec sec-type="data-availability">
                <title>Data availability statement</title>
                <p>Underlying data from this manuscript may be requested by qualified researchers 6 months
after product approval in the USA and/or Europe, or global development is discontinued,
and 18 months after trial completion. Investigators may request access to anonymized
individual patient-level data and redacted trial documents, which may include:
analysis-ready datasets, study protocol, annotated case report form, statistical analysis
plan, dataset specifications and clinical study report. Prior to use of the data,
proposals need to be approved by an independent review panel at <ext-link xlink:href="http://www.Vivli.org" ext-link-type="uri">www.Vivli.org</ext-link> and a signed data sharing
agreement will need to be executed. All documents are available in English only, for a
pre-specified time, typically 12 months, on a password-protected portal.</p>
              </sec>
              <sec>
                <title>Supplementary data</title>
                <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available
at <italic toggle="yes">Rheumatology</italic> online.</p>
              </sec>
            </ack>
            <ref-list id="ref1">
              <title>References</title>
              <ref id="keab381-B1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dema</surname><given-names>B</given-names></string-name>, <string-name><surname>Charles</surname><given-names>N.</given-names></string-name></person-group><article-title>Autoantibodies in SLE: specificities, isotypes and
receptors</article-title>.
<source>Antibodies</source><year>2016</year>;<volume>5</volume>:<fpage>2</fpage>.</mixed-citation>
              </ref>
              <ref id="keab381-B2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rahman</surname><given-names>A</given-names></string-name>, <string-name><surname>Isenberg</surname><given-names>DA.</given-names></string-name></person-group><article-title>Systemic lupus erythematosus</article-title>. <source>N Engl J
Med</source><year>2008</year>;<volume>358</volume>:<fpage>929</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">18305268</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ünlü</surname><given-names>O</given-names></string-name>, <string-name><surname>Zuily</surname><given-names>S</given-names></string-name>, <string-name><surname>Erkan</surname><given-names>D.</given-names></string-name></person-group><article-title>The clinical significance of antiphospholipid antibodies in systemic lupus
erythematosus</article-title>. <source>Eur J
Rheumatol</source><year>2016</year>;<volume>3</volume>:<fpage>75</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="pmid">27708976</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bruce</surname><given-names>IN</given-names></string-name>, <string-name><surname>O’Keeffe</surname><given-names>AG</given-names></string-name>,
<string-name><surname>Farewell</surname><given-names>V</given-names></string-name></person-group><etal>et al</etal><article-title>Factors associated with damage accrual in patients with systemic lupus
erythematosus: results from the Systemic Lupus International Collaborating Clinics
(SLICC) Inception Cohort</article-title>. <source>Ann Rheum
Dis</source><year>2015</year>;<volume>74</volume>:<fpage>1706</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">24834926</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Drenkard</surname><given-names>C</given-names></string-name>, <string-name><surname>Lim</surname><given-names>SS.</given-names></string-name></person-group><article-title>Update on lupus epidemiology: advancing health disparities research through
the study of minority populations</article-title>. <source>Curr Opin
Rheumatol</source><year>2019</year>;<volume>31</volume>:<fpage>689</fpage>–<lpage>96</lpage>.<pub-id pub-id-type="pmid">31436582</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Margery-Muir</surname><given-names>AA</given-names></string-name>, <string-name><surname>Bundell</surname><given-names>C</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>D</given-names></string-name>, <string-name><surname>Groth</surname><given-names>DM</given-names></string-name>, <string-name><surname>Wetherall</surname><given-names>JD.</given-names></string-name></person-group><article-title>Gender balance in patients with systemic lupus
erythematosus</article-title>. <source>Autoimmun
Rev</source><year>2017</year>;<volume>16</volume>:<fpage>258</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="pmid">28137478</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rider</surname><given-names>V</given-names></string-name>, <string-name><surname>Abdou</surname><given-names>NI</given-names></string-name>, <string-name><surname>Kimler</surname><given-names>BF</given-names></string-name></person-group><etal>et al</etal><article-title>Gender bias in human systemic lupus erythematosus: a problem of steroid
receptor action?</article-title><source>Front Immunol</source><year>2018</year>;<volume>9</volume>:<fpage>611</fpage>.<pub-id pub-id-type="pmid">29643853</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rees</surname><given-names>F</given-names></string-name>, <string-name><surname>Doherty</surname><given-names>M</given-names></string-name>, <string-name><surname>Grainge</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>The incidence and prevalence of systemic lupus erythematosus in the UK,
1999–2012</article-title>. <source>Ann Rheum
Dis</source><year>2016</year>;<volume>75</volume>:<fpage>136</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">25265938</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Al Dhanhani</surname><given-names>AM</given-names></string-name>, <string-name><surname>Agarwal</surname><given-names>M</given-names></string-name>, <string-name><surname>Othman</surname><given-names>YS</given-names></string-name>, <string-name><surname>Bakoush</surname><given-names>O.</given-names></string-name></person-group><article-title>Incidence and prevalence of systemic lupus erythematosus among the native
Arab population in UAE</article-title>.
<source>Lupus</source><year>2017</year>;<volume>26</volume>:<fpage>664</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">27831539</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dall'era</surname><given-names>M</given-names></string-name>, <string-name><surname>Cisternas</surname><given-names>MG</given-names></string-name>,
<string-name><surname>Snipes</surname><given-names>K</given-names></string-name></person-group><etal>et al</etal><article-title>The incidence and prevalence of systemic lupus erythematosus in San
Francisco County, California: the California Lupus Surveillance Project</article-title>.
<source>Arthritis
Rheumatol</source><year>2017</year>;<volume>69</volume>:<fpage>1996</fpage>–<lpage>2005</lpage>.<pub-id pub-id-type="pmid">28891237</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fatoye</surname><given-names>F</given-names></string-name>, <string-name><surname>Gebrye</surname><given-names>T</given-names></string-name>, <string-name><surname>Svenson</surname><given-names>LW.</given-names></string-name></person-group><article-title>Real-world incidence and prevalence of systemic lupus erythematosus in
Alberta, Canada</article-title>. <source>Rheumatol
Int</source><year>2018</year>;<volume>38</volume>:<fpage>1721</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">29987494</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Osio-Salido</surname><given-names>E</given-names></string-name>, <string-name><surname>Manapat-Reyes</surname><given-names>H.</given-names></string-name></person-group><article-title>Epidemiology of systemic lupus erythematosus in Asia</article-title>.
<source>Lupus</source><year>2010</year>;<volume>19</volume>:<fpage>1365</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">20947544</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zou</surname><given-names>YF</given-names></string-name>, <string-name><surname>Feng</surname><given-names>CC</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>JM</given-names></string-name></person-group><etal>et al</etal><article-title>Prevalence of systemic lupus erythematosus and risk factors in rural areas
of Anhui Province</article-title>. <source>Rheumatol
Int</source><year>2014</year>;<volume>34</volume>:<fpage>347</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">24264010</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mosca</surname><given-names>M</given-names></string-name>, <string-name><surname>Tani</surname><given-names>C</given-names></string-name>, <string-name><surname>Carli</surname><given-names>L</given-names></string-name>, <string-name><surname>Bombardieri</surname><given-names>S.</given-names></string-name></person-group><article-title>Glucocorticoids in systemic lupus erythematosus</article-title>.
<source>Clin Exp
Rheumatol</source><year>2011</year>;<volume>29</volume>:<fpage>S126</fpage>–<lpage>9</lpage>.</mixed-citation>
              </ref>
              <ref id="keab381-B15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Judd</surname><given-names>LL</given-names></string-name>, <string-name><surname>Schettler</surname><given-names>PJ</given-names></string-name>,
<string-name><surname>Brown</surname><given-names>ES</given-names></string-name></person-group><etal>et al</etal><article-title>Adverse consequences of glucocorticoid medication: psychological,
cognitive, and behavioral effects</article-title>. <source>Am J
Psychiatry</source><year>2014</year>;<volume>171</volume>:<fpage>1045</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">25272344</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ruiz-Irastorza</surname><given-names>G</given-names></string-name>, <string-name><surname>Danza</surname><given-names>A</given-names></string-name>, <string-name><surname>Khamashta</surname><given-names>M.</given-names></string-name></person-group><article-title>Glucocorticoid use and abuse in SLE</article-title>. <source>Rheumatology
(Oxford</source>)
<year>2012</year>;<volume>51</volume>:<fpage>1145</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">22271756</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dall’era</surname><given-names>M</given-names></string-name>, <string-name><surname>Bruce</surname><given-names>IN</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>C</given-names></string-name></person-group><etal>et al</etal><article-title>Current challenges in the development of new treatments for
lupus</article-title>. <source>Ann Rheum
Dis</source><year>2019</year>;<volume>78</volume>:<fpage>729</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">30636212</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mahieu</surname><given-names>MA</given-names></string-name>, <string-name><surname>Strand</surname><given-names>V</given-names></string-name>, <string-name><surname>Simon</surname><given-names>LS</given-names></string-name>, <string-name><surname>Lipsky</surname><given-names>PE</given-names></string-name>, <string-name><surname>Ramsey-Goldman</surname><given-names>R.</given-names></string-name></person-group><article-title>A critical review of clinical trials in systemic lupus
erythematosus</article-title>.
<source>Lupus</source><year>2016</year>;<volume>25</volume>:<fpage>1122</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">27497257</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yazdany</surname><given-names>J</given-names></string-name>, <string-name><surname>Davis</surname><given-names>J.</given-names></string-name></person-group><article-title>The role of CD40 ligand in systemic lupus erythematosus</article-title>.
<source>Lupus</source><year>2004</year>;<volume>13</volume>:<fpage>377</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">15230296</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Daoussis</surname><given-names>D</given-names></string-name>, <string-name><surname>Andonopoulos</surname><given-names>AP</given-names></string-name>,
<string-name><surname>Liossis</surname><given-names>S-NC.</given-names></string-name></person-group><article-title>Targeting CD40L: a promising therapeutic approach</article-title>.
<source>Clin Diagn Lab
Immunol</source><year>2004</year>;<volume>11</volume>:<fpage>635</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">15242934</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Comte</surname><given-names>D</given-names></string-name>, <string-name><surname>Karampetsou</surname><given-names>MP</given-names></string-name>,
<string-name><surname>Tsokos</surname><given-names>GC.</given-names></string-name></person-group><article-title>T cells as a therapeutic target in SLE</article-title>.
<source>Lupus</source><year>2015</year>;<volume>24</volume>:<fpage>351</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">25801878</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grammer</surname><given-names>AC</given-names></string-name>, <string-name><surname>Slota</surname><given-names>R</given-names></string-name>, <string-name><surname>Fischer</surname><given-names>R</given-names></string-name></person-group><etal>et al</etal><article-title>Abnormal germinal center reactions in systemic lupus erythematosus
demonstrated by blockade of CD154-CD40 interactions</article-title>. <source>J Clin
Invest</source><year>2003</year>;<volume>112</volume>:<fpage>1506</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">14617752</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>W</given-names></string-name>, <string-name><surname>Sinha</surname><given-names>J</given-names></string-name>, <string-name><surname>Newman</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal><article-title>The effect of anti-CD40 ligand antibody on B cells in human systemic lupus
erythematosus</article-title>. <source>Arthritis
Rheum</source><year>2002</year>;<volume>46</volume>:<fpage>1554</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">12115186</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Karnell</surname><given-names>JL</given-names></string-name>, <string-name><surname>Rieder</surname><given-names>SA</given-names></string-name>, <string-name><surname>Ettinger</surname><given-names>R</given-names></string-name>, <string-name><surname>Kolbeck</surname><given-names>R.</given-names></string-name></person-group><article-title>Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity
and beyond</article-title>. <source>Adv Drug Deliv
Rev</source><year>2019</year>;<volume>141</volume>:<fpage>92</fpage>–<lpage>103</lpage>.<pub-id pub-id-type="pmid">30552917</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boumpas</surname><given-names>DT</given-names></string-name>, <string-name><surname>Furie</surname><given-names>R</given-names></string-name>, <string-name><surname>Manzi</surname><given-names>S</given-names></string-name></person-group><etal>et al</etal>; <collab>on behalf of the BG9588 Lupus Nephritis Trial Group</collab>.
<article-title>A short course of BG9588 (anti-CD40 ligand antibody) improves serologic
activity and decreases hematuria in patients with proliferative lupus
glomerulonephritis</article-title>. <source>Arthritis
Rheum</source><year>2003</year>;<volume>48</volume>:<fpage>719</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">12632425</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robles-Carrillo</surname><given-names>L</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>T</given-names></string-name>, <string-name><surname>Hatfield</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>Anti-CD40L immune complexes potently activate platelets in vitro and cause
thrombosis in FCGR2A transgenic mice</article-title>. <source>J
Immunol</source><year>2010</year>;<volume>185</volume>:<fpage>1577</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">20585032</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shock</surname><given-names>A</given-names></string-name>, <string-name><surname>Burkly</surname><given-names>L</given-names></string-name>, <string-name><surname>Wakefield</surname><given-names>I</given-names></string-name></person-group><etal>et al</etal><article-title>CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits
CD40L-dependent immune responses without thrombotic complications: an in vivo
study</article-title>. <source>Arthritis Res
Ther</source><year>2015</year>;<volume>17</volume>:<fpage>234</fpage>.<pub-id pub-id-type="pmid">26335795</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tocoian</surname><given-names>A</given-names></string-name>, <string-name><surname>Buchan</surname><given-names>P</given-names></string-name>, <string-name><surname>Kirby</surname><given-names>H</given-names></string-name></person-group><etal>et al</etal><article-title>First-in-human trial of the safety, pharmacokinetics and immunogenicity of
a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients
with systemic lupus erythematosus</article-title>.
<source>Lupus</source><year>2015</year>;<volume>24</volume>:<fpage>1045</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">25784719</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chamberlain</surname><given-names>C</given-names></string-name>, <string-name><surname>Colman</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Ranger</surname><given-names>AM</given-names></string-name></person-group><etal>et al</etal><article-title>Repeated administration of dapirolizumab pegol in a randomised phase I
study is well tolerated and accompanied by improvements in several composite measures of
systemic lupus erythematosus disease activity and changes in whole blood transcriptomic
profiles</article-title>. <source>Ann Rheum
Dis</source><year>2017</year>;<volume>76</volume>:<fpage>1837</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">28780512</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bretz</surname><given-names>F</given-names>, </string-name><string-name><surname>Pinheiro</surname><given-names>JC</given-names>, </string-name><string-name><surname>Branson</surname><given-names>M.</given-names></string-name></person-group><article-title>Combining multiple comparisons and modeling techniques in dose-response
studies</article-title>.
<source>Biometrics</source><year>2005</year>;<volume>61</volume>:<fpage>738</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">16135025</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Furie</surname><given-names>RA</given-names></string-name>, <string-name><surname>Petri</surname><given-names>MA</given-names></string-name>, <string-name><surname>Wallace</surname><given-names>DJ</given-names></string-name></person-group><etal>et al</etal><article-title>Novel evidence-based systemic lupus erythematosus responder
index</article-title>. <source>Arthritis
Rheum</source><year>2009</year>;<volume>61</volume>:<fpage>1143</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">19714615</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Merrill</surname><given-names>JT</given-names></string-name>, <string-name><surname>Van
Vollenhoven</surname><given-names>RF</given-names></string-name>, <string-name><surname>Buyon</surname><given-names>JP</given-names></string-name></person-group><etal>et al</etal><article-title>Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to
B-cell activating factor, in patients with systemic lupus erythematosus: results from
ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind,
placebo-controlled study</article-title>. <source>Ann Rheum
Dis</source><year>2016</year>;<volume>75</volume>:<fpage>332</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">26293163</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wallace</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Strand</surname><given-names>V</given-names></string-name>, <string-name><surname>Merrill</surname><given-names>JT</given-names></string-name></person-group><etal>et al</etal><article-title>Efficacy and safety of an interleukin 6 monoclonal antibody for the
treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled
trial</article-title>. <source>Ann Rheum
Dis</source><year>2017</year>;<volume>76</volume>:<fpage>534</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">27672124</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Furie</surname><given-names>R</given-names></string-name>, <string-name><surname>Petri</surname><given-names>M</given-names></string-name>, <string-name><surname>Zamani</surname><given-names>O</given-names></string-name></person-group><etal>et al</etal>; <collab>BLISS-76 Study Group</collab>. <article-title>A phase III,
randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B
lymphocyte stimulator, in patients with systemic lupus erythematosus</article-title>.
<source>Arthritis
Rheum</source><year>2011</year>;<volume>63</volume>:<fpage>3918</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">22127708</pub-id></mixed-citation>
              </ref>
              <ref id="keab381-B35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Navarra</surname><given-names>SV</given-names></string-name>, <string-name><surname>Guzmán</surname><given-names>RM</given-names></string-name>, <string-name><surname>Gallacher</surname><given-names>AE</given-names></string-name></person-group><etal>et al</etal><article-title>Efficacy and safety of belimumab in patients with active systemic lupus
erythematosus: a randomised, placebo-controlled, phase 3 trial</article-title>.
<source>Lancet</source><year>2011</year>;<volume>377</volume>:<fpage>721</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">21296403</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
